HeartBeam Buy Rating Reiterated as Clinical and Commercial Momentum Strengthens; $2 Price Target Maintained
I'm LongbridgeAI, I can summarize articles.Maxim Group analyst Anthony Vendetti reiterated a Buy rating on HeartBeam with a $2 price target, citing strong clinical and commercial momentum. Key drivers include the accelerated enrollment of the ALIGN-ACS heart attack detection program, real-world validation from the HEADSTART-ACS study, and early revenue traction from the commercial launch of the arrhythmia-focused HeartBeam System. The recommendation is supported by a solid cash position and DCF valuation. Benchmark Co. also maintained a Buy rating with a $5 target.
Maxim Group analyst Anthony Vendetti maintained a Buy rating on HeartBeam yesterday and set a price target of $2.00.
Summer Sale - Claim 70% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Anthony Vendetti has given his Buy rating due to a combination of factors tied to HeartBeam’s advancing clinical, commercial, and strategic position. The company has rapidly progressed its ALIGN-ACS heart attack detection program, completing enrollment ahead of schedule and moving toward pivotal testing and potential FDA approval, while simultaneously demonstrating real-world validation through the HEADSTART-ACS study supported by the Indonesian government.
At the same time, HeartBeam’s arrhythmia-focused HeartBeam System is in a soft commercial launch with growing orders, active 24/7 reader services, and early patient onboarding, indicating emerging revenue traction. Vendetti also points to the novel ECG platform, sizeable unmet need in ambulatory cardiac diagnostics, a solid cash position to fund near-term operations, and a DCF-based valuation framework that supports a $2 price target, unchanged from prior, as reasons to maintain the Buy recommendation.
Vendetti covers the Healthcare sector, focusing on stocks such as Sintx Technologies, PAVmed, and Dermata Therapeutics. According to TipRanks, Vendetti has an average return of -19.2% and a 27.79% success rate on recommended stocks.
In another report released on August 14, Benchmark Co. also reiterated a Buy rating on the stock with a $5.00 price target.